biota

Biota Holdings Limited
ACN 006 479 081
10/585 Blackburn Road
Notting Hill VIC 3168
Australia
T +61 3 9915 3700
F +61 3 9915 3702
E info@biota.com.au
W www.biota.com.au

For Immediate Release

Melbourne, Australia — 11 May 2012

Inavir® Phase III prevention study update

Biota Holdings Limited (ASX:BTA) provides the following update on the Japanese Phase III prevention study for the influenza antiviral, laninamivir (Inavir®) by Daiichi Sankyo.

Daiichi Sankyo has advised that enrolment has been completed. Summary results of the study will be provided after review with the study investigator.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo Co., Ltd. co-own a range of second generation influenza antivirals, of which the lead product Inavir®, is marketed in Japan. Biota holds a contract from the US Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA.

Investor / Analyst Enquiries
Biota Holdings Limited
Peter Cook
T: +61 3 9915 3720
Damian Lismore
T: +61 3 9915 3721

Media Enquiries
Tim Duncan, Hinton & Associates
T: +61 3 9600 1979 / M: +61 408 441 122

US Enquiries
Hershel Berry, Blueprint Life Science Group
M: +1 415 505 3749